Data

Click on Protocol Number of interest to view study-related documentation or download data files. (DTMC data files are under development.)
Division Study Number Title Sort descending Investigator(s) Release Date
DTMC NIDA-CPU-0008 Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil Reese Jones, M.D. Dec 21, 2017
DTMC NIDA-CPU-0016 Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) Eugene Somoza, M.D. Dec 04, 2014
DTMC NIDA-CSP-1021 Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence Liza Gorgon, M.A. May 07, 2018
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D. Aug 01, 2016
DTMC NIDA-CSP-1019 Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D. May 07, 2018
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
DTMC NIDA-CTO-0011 Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D. Jan 15, 2019
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
CTN NIDA-CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment John Rotrosen, M.D. Jan 12, 2018
CTN NIDA-CTN-0017 HIV and HCV Risk Reduction Interventions in Drug Detoxification and Treatment Settings Robert Booth, Ph.D. Dec 23, 2008